Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Jessica Louw"'
Autor:
Takeo Fujii, James M Reuben, Lei Huo, Jose Rodrigo Espinosa Fernandez, Yun Gong, Rachel Krupa, Mahipal V Suraneni, Ryon P Graf, Jerry Lee, Stephanie Greene, Angel Rodriguez, Lyndsey Dugan, Jessica Louw, Bora Lim, Carlos H Barcenas, Angela N Marx, Debu Tripathy, Yipeng Wang, Mark Landers, Ryan Dittamore, Naoto T Ueno
Publikováno v:
PLoS ONE, Vol 12, Iss 9, p e0185231 (2017)
Androgen receptor (AR) is frequently detected in breast cancers, and AR-targeted therapies are showing activity in AR-positive (AR+) breast cancer. However, the role of AR in breast cancers is still not fully elucidated and the biology of AR in breas
Externí odkaz:
https://doaj.org/article/03d577abb63d4dd384a30274ba5974ae
Autor:
David Lu, Ryon P. Graf, Melissa Harvey, Ravi A. Madan, Christopher Heery, Jennifer Marte, Sharon Beasley, Kwong Y. Tsang, Rachel Krupa, Jessica Louw, Justin Wahl, Natalee Bales, Mark Landers, Dena Marrinucci, Jeffrey Schlom, James L. Gulley, Ryan Dittamore
Publikováno v:
Journal of Circulating Biomarkers, Vol 4 (2015)
Retrospective analysis of patient tumour samples is a cornerstone of clinical research. CTC biomarker characterization offers a non-invasive method to analyse patient samples. However, current CTC technologies require prospective blood collection, th
Externí odkaz:
https://doaj.org/article/d4a24030272e4528acf9e11179e93cbf
Autor:
Jorge Nieva, Ryan V. Dittamore, Lyudmila Bazhenova, Samir Makani, Marisa Magaña, Stephanie B. Greene, Mahipal Suraneni, Mark Landers, Yipeng Wang, Lyndsey Dugan, Jessica Louw, Rachel Krupa, David Lu, Jessica Hoag, Michelle C. Salazar, Ryon P. Graf, Daniel J. Boffa
Assessment of PD-L1 Assay Sensitivity and Specificity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ee4a84903304748cde92695267aa7db
https://doi.org/10.1158/1055-9965.22436826
https://doi.org/10.1158/1055-9965.22436826
Autor:
Howard I. Scher, Ryan Dittamore, Dena Marrinucci, Scott T. Tagawa, David M. Nanus, Nicole A. Schreiber, Ryon P. Graf, Rachel Krupa, Jessica Louw, Myriam Kossai, Juan Miguel Mosquera, Mark Landers, Adam Jendrisak, Himisha Beltran
Figure S1: Examples of a decision boundary that separate class A (red) from class B (blue) in 1 dimension (figure 1A) and 2 dimensions (figure 1B); Figure S2: Schematic of the supervised learning process (A) and leave one out cross validation (B); Fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec9b853ef189603226c86b6b11fd33d9
https://doi.org/10.1158/1078-0432.22459598.v1
https://doi.org/10.1158/1078-0432.22459598.v1
Autor:
Jorge Nieva, Ryan V. Dittamore, Lyudmila Bazhenova, Samir Makani, Marisa Magaña, Stephanie B. Greene, Mahipal Suraneni, Mark Landers, Yipeng Wang, Lyndsey Dugan, Jessica Louw, Rachel Krupa, David Lu, Jessica Hoag, Michelle C. Salazar, Ryon P. Graf, Daniel J. Boffa
Background: Lung cancer treatment has become increasingly dependent upon invasive biopsies to profile tumors for personalized therapy. Recently, tumor expression of programmed death-ligand 1 (PD-L1) has gained interest as a potential predictor of res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25351a2a77e04e2326f7efe9f07e9334
https://doi.org/10.1158/1055-9965.c.6515595
https://doi.org/10.1158/1055-9965.c.6515595
Autor:
Howard I. Scher, Ryan Dittamore, Dena Marrinucci, Scott T. Tagawa, David M. Nanus, Nicole A. Schreiber, Ryon P. Graf, Rachel Krupa, Jessica Louw, Myriam Kossai, Juan Miguel Mosquera, Mark Landers, Adam Jendrisak, Himisha Beltran
Purpose: The transition of prostate adenocarcinoma to a predominantly androgen receptor (AR) signaling independent phenotype can occur in the later stages of the disease and is associated with low AR expression +/− the development of small-cell or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6437742746c507d642175adc86f3c0f9
https://doi.org/10.1158/1078-0432.c.6524261.v1
https://doi.org/10.1158/1078-0432.c.6524261.v1
Autor:
Jorge Nieva, Ryan V. Dittamore, Lyudmila Bazhenova, Samir Makani, Marisa Magaña, Stephanie B. Greene, Mahipal Suraneni, Mark Landers, Yipeng Wang, Lyndsey Dugan, Jessica Louw, Rachel Krupa, David Lu, Jessica Hoag, Michelle C. Salazar, Ryon P. Graf, Daniel J. Boffa
Cox Proportional Hazards Model of Patients With Confirmed Lung Cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c9254637fad7da6fbf250f45aa9d200
https://doi.org/10.1158/1055-9965.22436817.v1
https://doi.org/10.1158/1055-9965.22436817.v1
Autor:
Ines Figueiredo, Natalee Bales, Daniel Nava Rodrigues, Lukas C. Amler, Ruth Riisnaes, Yibing Yan, Sankar Mohan, Edith Szafer-Glusman, Aurelius Omlin, Gerhardt Attard, Dena Marrinucci, Eric Tucker, Elizabeth Punnoose, Roberta Ferraldeschi, Carmel Pezaro, Shannon L. Werner, Penelope Flohr, Jin Zhu, Johann S. de Bono, Premal Patel, Jessica Louw, Ajay Pandita, Susana Miranda
Publikováno v:
British Journal of Cancer
Background: PTEN gene loss occurs frequently in castration-resistant prostate cancer (CRPC) and may drive progression through activation of the PI3K/AKT pathway. Here, we developed a novel CTC-based assay to determine PTEN status and examined the cor
Autor:
Stephanie B. Greene, Howard I. Scher, Pascal Bamford, Nicole A. Schreiber, Adam Jendrisak, Mark Landers, Glenn Heller, Martin Fleisher, Ryan Dittamore, Rachel Krupa, Jessica Louw, Lyndsey Dugan, Ryon P. Graf, David S.K. Lu, Brigit McLaughlin, Hebert Alberto Vargas, Jerry Lee, Yipeng Wang
Publikováno v:
Cancer research. 77(20)
The heterogeneity of an individual patient's tumor has been linked to treatment resistance, but quantitative biomarkers to rapidly and reproducibly evaluate heterogeneity in a clinical setting are currently lacking. Using established tools available
Autor:
Hebert Alberto Vargas, Daniel C. Danila, Adam Jendrisak, Martin Fleisher, Ann Johnson, Ryon P. Graf, David S.K. Lu, Stephanie B. Greene, Ryan Dittamore, Brigit McLaughlin, Dena Marrinucci, Howard I. Scher, Glenn Heller, Jessica Louw, Nicole A. Schreiber, Justin Wahl, Richard Martin Bambury
Importance A critical decision in the management of metastatic castration-resistant prostate cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a taxane. Objective To determine if pretherapy nuclear androgen-recept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12e5435a181a77957b198c764d332fda
https://europepmc.org/articles/PMC5206761/
https://europepmc.org/articles/PMC5206761/